Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from a Cohort Study from the Alzheimer's Research and Treatment Center. (PubMed, Curr Alzheimer Res) - Oct 15, 2026 - "The subcutaneous lecanemab formulation was highly preferred by patients and care partners, with feedback highlighting reduced treatment burden and strong acceptability."
Journal • Alzheimer's Disease • CNS Disorders
|
|
Cynthia Bouchard; David Watson; Mark Stafford; Michael G Neam; Sydney Werner; Venessa Ranney
|